CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

12-827/S009, S010, S011

Trade Name: Robinul & Robinul Forte Tablets

Generic Name: (glycopyrrolate)

Sponsor: A.H. Robins Company

Approval Date: February 18, 1976

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

12-827/S009, S010, S011

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Approvable Letter	
Labeling	
Summary Review	
Officer/Employee List	
Office Director Memo	
Cross Discipline Team Leader Review	
Medical Review(s)	
Chemistry Review(s)	X
Environmental Assessment	
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/Biopharmaceutics Review(s)	
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	
Administrative/Correspondence Document(s)	X

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 12-827/S009, S010, S011

APPROVAL LETTER

NDA 12-827/S-009, S-010, S-011

FEB 18 1976

A. H. Robins Company
Attention: A. M. Stranz
1407 Cummings Drive
Richmond, Virginia 23220

Gentlemen:

Reference is made to your supplemental new drug applications dated November 14, 1975, (S-009) January 5, 1976, (S-010) and January 6, 1976, (S-011) submitted pursuant to section 505(b) of the Federal Food, Drug, and Cosmetic Act for Robinul and Robinul Forte (glycopyrrolate) Tablets.

The supplemental applications provide for revisions in the specifications applied to the raw materials to conform to the USP XIX and N.F. XIV (S-009) and the use of a five year expiration date on Robinul Tablets (S-010) and Robinul Forte Tablets (S-011) packaged in amber glass bottles with metal or screw caps.

We have completed the review of these supplemental new drug applications, and they are approved. Our letter dated December 17, 1975, detailed the conditions relating to the approval of this application.

In the future, it is recommended that the assay results be reported in percent of label claim in addition to percent of initial assay.

Sincerely yours,

EDBelt 2/12/76

E. DeVaughn Belton, M.D.
Director
Division of Cardio-Renal
Drug Products
Bureau of Drugs

cc: BLT-DO
Orig
HFD-110
HFD-110/SCSO
HFD-616
HFL-10
HFD-110/RJWolters/JFLangston/1/27/76/skc/2/2/76
R/D init by: RJWolters 1/27/76, JLangston 1/28/76, EDBelton 1/29/76

APPROVAL

RJWolters 2-11-76 JLangston 2/11/76

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 12-827/S009, S010, S011

CHEMISTRY REVIEW(S)

CHEMIST'S REVIEW
(If necessary, continue any item on 8" x 10½" paper. Key continuation to item by number.)

1. ORGANIZATION: HFD-110

2. NDA NUMBER: 12-827

3. NAME AND ADDRESS OF APPLICANT *(City and State)*: A. H. Robins Company, Richmond, Virginia 23220

DATE NDA APPROVED: 8-11-61

4. AF NUMBER: 16-375

5. SUPPLEMENT (S)

NUMBER(S)	DATE(S)
S-009	11-14-75
S-010	1-5-76
S-011	1-6-76

6. NAME OF DRUG: Robinul and Robinul Forte

7. NONPROPRIETARY NAME: Glycopyrrolate

8. SUPPLEMENT(S) PROVIDES FOR:
S-009 provides for revisions in the specifications applied to the raw materials to conform to the USP XIX and NF XIV.

S-010 and S-011 provide for a 5 year expiration date for Robinul and Robinul Fortee.

9. AMENDMENTS AND OTHER *(Reports, etc.)* DATES

10. PHARMACOLOGICAL CATEGORY: Anticholinergic

11. HOW DISPENSED: [X] RX [ ] OTC

12. RELATED IND/NDA/DMF(S)

13. DOSAGE FORM (S): Oral tablets

14. POTENCY *(ies)*: 1 mg and 2 mg (Forte)

15. CHEMICAL NAME AND STRUCTURE: See NF XIV

16. RECORDS AND REPORTS

CURRENT: [X] YES [ ] NO

REVIEWED: [X] YES [ ] NO

17. COMMENTS

Supplement S-009 was submitted to revised the specifications and tests applied to the raw materials to conform to the revisions in the USP XIX and NF XIV. All of the compendium specifications and tests are performed on the raw materials with the exception of b(4) The NDA has a pH specification of b(4) while the USP XIX specification is 4.5 to 7.0. This difference in the pH specification will not appreciably change the quality or purity of b(4) Satisfactory. S-010 and S-011 contained stability data on / lots of the tablets packaged in amber glass bottles with metal screw caps. The conditions were / months at — C; / year at — C; and / years at RT. The assay and disintegration results are satisfactory. Recommend to firm that in the future they report the assay results in percent of label claim in addition to percent of initial assay. b(4)

18. CONCLUSIONS AND RECOMMENDATIONS

Approve the supplements.

19. REVIEWER

NAME	SIGNATURE	DATE COMPLETED
R. J. Wolters	R J Wolters 2-71-76	FEB 18 1976 1-27-76

DISTRIBUTION: [X] ORIGINAL JACKET [ ] REVIEWER [ ] DIVISION FILE

FORM FDH 2266 (7/75) PREVIOUS EDITION MAY BE USED UNTIL SUPPLY IS EXHAUSTED.

ORIG NDA, HFD-110, HFD-110/SCSO, HFD-110/RJWolters/dsc/1-27-76

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 12-827/S009, S010, S011

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

NDA 12-827

JAN 28 1976

A. H. Robins Company
Attention: A. M. Stranz
1407 Cummings Drive
Richmond, Virginia 23220

Gentlemen:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: Robinul Forte Tablets

NDA Number: 12-827

Supplement Number: S-011

Date of Supplement: January 6, 1976

Date of Receipt: January 9, 1976

All communications concerning this NDA should be addressed as follows:

Bureau of Drugs HFD-110
Attention: DOCUMENT CONTROL ROOM #16B-30
5600 Fishers Lane
Rockville, Maryland 20852

Sincerely yours,

THD 1/26/76
Thomas H. Davis
Supervisory Consumer Safety Officer
Division of Cardio-Renal
Drug Products
Bureau of Drugs

cc: BLT-DO
NDA Orig.
HFD-110
HFD-110/SCSO
HFD-110/ALBrown/cg/1/23/76

SUPPLEMENT ACKNOWLEDGEMENT

NDA 12-827

JAN 22 1976

A. H. Robins Company
Attention: A. M. Stranz
1407 Cummings Drive
Richmond, Virginia 23220

Gentlemen:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: Robinul and Robinul Forte

NDA Number: 12-827

Supplement Number: S-009

Date of Supplement: November 14, 1975

Date of Receipt: January 5, 1976

All communications concerning this NDA should be addressed as follows:

Bureau of Drugs HFD-110
Attention: DOCUMENT CONTROL ROOM #16B-30
5600 Fishers Lane
Rockville, Maryland 20852

Sincerely yours,

THD 1/21/76

Thomas H. Davis
Supervisory Consumer Safety Officer
Division of Cardio-Renal
Drug Products
Bureau of Drugs

cc: BLT-DO
NDA Orig.
HFD-110
HFD-110/SCSO
HFD-110/ALBrown/1/19/76/ep/1/20/76

SUPPLEMENT ACKNOWLEDGEMENT

NDA 12-827

A. H. Robins Company
Attention: A. N. Stranz
1407 Cummings Drive
Richmond, Virginia 23220

JAN 28 1976

Gentlemen:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: Robinul Tablets

NDA Number: 12-827

Supplement Number: S-010

Date of Supplement: January 5, 1976

Date of Receipt: January 8, 1976

All communications concerning this NDA should be addressed as follows:

Bureau of Drugs HFD-110
Attention: DOCUMENT CONTROL ROOM #16B-30
5600 Fishers Lane
Rockville, Maryland 20852

Sincerely yours,

T H Davis 1/26/76

Thomas H. Davis
Supervisory Consumer Safety Officer
Division of Cardio-Renal
Drug Products
Bureau of Drugs

cc: BLT-DO
NDA Orig.
HFD-110
HFD-110/SCSO
HFD-110/ALBrown/cg/1/23/76

SUPPLEMENT ACKNOWLEDGEMENT

A. M. Stranz
Manager, Drug Registration

A. H. Robins Company
1407 Cummings Drive
Richmond, Virginia 23220
Telephone (804) 257-2546

ORIGINAL

A-H-ROBINS

NDA NO. 12-827 REF. NO. 5011
NDA SUPPL FOR Expiration

Bureau of Drugs HFD-110
Room 16-B-30
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20852

CE

Noted.
H M Robins MD
2/3/76
Refer to Chemist

January 6, 1976

Re: NDA 12-827
Robinul Forte Tablets

Gentlemen:

This manufacturing supplement to our New Drug Application for Robinul Forte Tablets is submitted under the provisions of paragraph 314.8(a)(5)(ix) which permits the initiation of expiration dating prior to approval of an NDA supplement.

An expiration date of five years will be revealed on the immediate container labels of all Robinul Forte Tablets packaged after January 1, 1976. This revision in label information is made to comply with the National Formulary XIV which became official in July 1975.

Enclosed in triplicate are copies of the 5-year stability summary for this product and copies of [redacted] used to obtain the results. b(4)

Enclosed also are twelve (12) example labels which illustrate this new development. Any future change in the dating period established by this submission will be proposed in a supplemental application and will not be put into effect until the supplement is approved.

All other sections of the NDA remain unchanged.

Sincerely,

A. M. Stranz

rmv
Enclosures: 5-year stability summary for Lots 63, 64, 65
[redacted] b(4)
Labels



8 Page(s) Withheld

1 Trade Secret / Confidential (b4)

_____ Draft Labeling (b4)

_____ Draft Labeling (b5)

_____ Deliberative Process (b5)

Withheld Track Number: Administrative- 12-872
S009, S010
S011

A. M. Stranz
Manager, Drug Registration

A. H. Robins Company
1407 Cummings Drive
Richmond, Virginia 23220
Telephone (804) 257-2546

ORIGINAL

CE

NDA NO. 12827 REF. NO. 5010

NDA SUPPL FOR Expiration

A-H-ROBINS

Bureau of Drugs HFD-110
Room 16-B-30
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20852

Noted.
A. H. Robins
2/3/76
Refer to Chemist

January 5, 1976

Re: NDA 12-827
Robinul Tablets

Gentlemen:

This manufacturing supplement to our New Drug Application for Robinul Tablets is submitted under the provisions of paragraph 314.8(a) (5) (ix) which permits the initiation of expiration dating prior to approval of an NDA supplement.

An expiration date of five years will be revealed on the immediate container labels of all Robinul Tablets packaged after January 1, 1976. This revision in label information is made to comply with the National Formulary XIV which became official in July 1975.

Enclosed in triplicate are copies of the 5-year stability summary for this product and copies of [redacted] used to obtain the results. b(4)

Enclosed also are twelve (12) example labels which illustrate this new development. Any future change in the dating period established by this submission will be proposed in a supplemental application and will not be put into effect until the supplement is approved.

All other sections of the NDA remain unchanged.

Sincerely,

A. M. Stranz

RECEIVED
JAN 8 1976
BUREAU OF DRUGS

rmv
Enclosures: 5-year stability summary for Lots 231, 232, 233
Labels b(4)

7 Page(s) Withheld

1 Trade Secret / Confidential (b4)

_____ Draft Labeling (b4)

_____ Draft Labeling (b5)

_____ Deliberative Process (b5)

Withheld Track Number: Administrative-12827
S009, S010, S011

A. M. Stranz
Manager Drug Registration

ORIGINAL

A. H. Robins Company
1407 Cummings Drive
Richmond, Virginia 23220
Telephone (804) 257-2546

NDA NO. 12-827 SEE NO. S002
NDA SUPPL FOR Controls

A-H-ROBINS

E. DeVaughn Belton, M.D.
Director
Division of Cardio-Renal
Drug Products
Bureau of Drugs HFD 110
Room 16B-03
5600 Fishers Lane
Rockville, Maryland 20852

CS
Noted
A.H. Robins MC
1/23/76
Refer to Chemist

November 14, 1975

SUBJECT: Changes in Publications and Official Pharmacopoeial Standard Substances Reference USP XIX and/or NF XIV 1975

NDA #12-827
Robinul and Robinul Forte
Citation 21CRF §314.8

Gentlemen:

This is a supplement to our New Drug Application for Robinul and Robinul Forte Tablets NDA #12-827.

It is submitted under the provisions of 21CFR §314.8 for the purposes cited above.

Upon the appearance of the new editions of the recognized U.S. pharmacopoeias, a corresponding change is made in our raw material and test procedures found in our respective new drug applications. Since the USP and NF were automatically accorded recognition in July 1975, A. H. Robins has ensured that our drug products meet any new requirements found in the respective official monographs and/or standards.

RECEIVED
JAN 5 1976
HFD-110
BUREAU OF DRUGS

Enclosed are the following raw material pharmacopoeial specifications applied to the above-cited New Drug Application and referenced in the 1975 USP and/or NF

Robinul

1. Glycopyrrolate
2. b(4)
3. b(4)
4. b(4)
5. b(4)

Robinul Forte

1. Glycopyrrolate b(4)
2. b(4)
3. b(4)
4. b(4)
5. b(4)

Sincerely,

A. M. Stranz

ns

7 Page(s) Withheld

✓ Trade Secret / Confidential (b4)

_____ Draft Labeling (b4)

_____ Draft Labeling (b5)

_____ Deliberative Process (b5)

Withheld Track Number: Administrative- 12-827
S009, S010
S011

NOTICE OF APPROVAL
NEW DRUG APPLICATION OR SUPPLEMENT

NDA NUMBER: 12-827/S-009, S-010, S-011

DATE APPROVAL LETTER ISSUED: FEB 18 1976

TO: Press Relations Staff *(PA-40)*

FROM: [X] Bureau of Drugs [ ] Bureau of Veterinary Medicine

ATTENTION

Forward original of this form for publication only after approval letter has been issued and the date of approval has been entered above.

TYPE OF APPLICATION: [ ] ORIGINAL NDA [X] SUPPLEMENT TO NDA [ ] ABBREVIATED ORIGINAL NDA [ ] SUPPLEMENT TO ANDA

CATEGORY: [X] HUMAN [ ] VETERINARY

TRADE NAME *(or other designated name)* AND ESTABLISHED OR NONPROPRIETARY NAME *(if any)* OF DRUG

Robinul and Robinul Forte (glycopyrrolate)

DOSAGE FORM: Tablet

HOW DISPENSED: [X] RX [ ] OTC

ACTIVE INGREDIENT(S) *(as declared on label. List by established or nonproprietary name(s) and include amount(s), if amount is declared on label.)*

Glycopyrrolate 1 mg and Forte 2 mg

NAME OF APPLICANT *(Include City and State)*

A. H. Robins Company
Richmond, Virginia 23220

PRINCIPAL INDICATION OR PHARMACOLOGICAL CATEGORY

Anticholinergic

COMPLETE FOR VETERINARY ONLY

ANIMAL SPECIES FOR WHICH APPROVED

COMPLETE FOR SUPPLEMENT ONLY

CHANGE APPROVED TO PROVIDE FOR

S-009 Controls revisions
S-010 and S-011 Expiration dates

FORM PREPARED BY

NAME: R. J. Wolters — DATE: 2-11-76

FORM APPROVED BY

NAME: J. F. Langston — DATE: 2/11/76

Form FD 1642 (4/73) PREVIOUS EDITION MAY BE USED UNTIL SUPPLY IS EXHAUSTED.

ORIG, HFD-110, HFD-110/SCSO, HFD-110/RJWolters/dsc/2:6:75, HFI-40